89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis
- 89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks Yahoo Finance
- Chasing Akero, 89bio reduces scarring in midphase NASH trial to hit primary goals, tee up phase 3 FierceBiotech
- 89bio’s stock rallies 48% on new NASH data MarketWatch
- Drug developer 89Bio soars as NASH drug succeeds in mid-stage study Reuters
- Why Is 89bio (ETNB) Stock Up 34% Today? InvestorPlace
- View Full Coverage on Google News
Read More: 89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis